Particularly in non-small cell lung cancer (NSCLC), where testing for biomarkers is widely practiced using either immunohistochemistry (IHC) or next-generation sequencing (NGS), this method has demonstrated significant efficacy.1, -3 Conceptually, reflex testing has expanded to various tumour types, including melanoma, and most notably B-Raf proto-oncogene (BRAF) mutated melanomas, which exhibit high sensitivity to BRAF- and MEK inhibitors. This evidence concerns the gene MAP2K7 and melanoma.